AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00689715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection
Description: A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
Study NCT04038788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD hf-tRNS
Description: See detail in arm/group descriptions regarding the intervention.
Study NCT04038788 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD hf-tRNS
Description: See detail in arm/group descriptions regarding the intervention.
Study NCT01688154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)
Study NCT01688154 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2 empty capsules
Study NCT00368511 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Music Listening
Description: Listen to music and posture measurements
Study NCT00790907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux background and standard dose UFH
Description: Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein \[GP\] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) \[maximum two additional bolus doses\]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
Study NCT00790907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux background and low dose heparin
Description: Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
Study NCT00790907 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Open label fondaparinux
Description: Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
Study NCT02022488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam
Description: Group M
Study NCT02022488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Group M
Study NCT02022488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: Group MA
Study NCT02022488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Group MK
Study NCT04434495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP injection into uterine cavity
Study NCT03115307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
Study NCT02666573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fotosan 630, CMS Dental, Copenhagen, Denmark
Description: The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
Study NCT02666573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scaling and root planing
Description: Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
Study NCT03775421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Description: macitentan 10 mg, film-coated tablet, oral use
Study NCT00805831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDH
Description: sutureless vascular anastomosis
Study NCT03410888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Popliteal approach
Description: Popliteal approach:~Under ultrasound guidance a 50 to 90 mm 22 G needle is inserted in and advanced to contact the target nerve until nerve movement is detected. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
Study NCT03410888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infragluteal approach
Description: Infragluteal approach: The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
Study NCT02199080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: D-dimer assay before ablation of atrial fibrillation
Description: Blood sample collection for D-dimers measurement
Study NCT04160507 — intervention group
Intervention type: OTHER
Intervention: Biorepository
Description: To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.
Study NCT03166293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive leg training with a physical therapist
Description: Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
Study NCT00446511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Study NCT00446511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Study NCT00446511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Study NCT00446511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo matched to enalapril
Description: Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Study NCT00446511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo matched to valsartan
Description: placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Study NCT00841685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldlock
Description: Insertion of Goldlock marker
Study NCT00841685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visicoil smallest size
Description: Insertion of Visicoil, smallest size, marker
Study NCT00841685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visicoil larger size
Description: Insertion of Visicoil, larger size, marker
Study NCT00841685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard goldmarker smallest size
Description: Insertion of Bard goldmarker, smallest size
Study NCT00841685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard goldmarker larger size
Description: Insertion of Bard goldmarker, larger size
Study NCT03482414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional wooden checkerboard
Description: upper limb training with traditional wooden checkerboard
Study NCT03811938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation
Description: Catheter ablation aiming for the electrical isolation of the pulmonary veins.
Study NCT03482414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaming board with single-player games
Description: upper limb training with a LED-based interactive gaming board equipped with single-player games
Study NCT01783704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
Study NCT03482414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaming board with two-player games
Description: upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
Study NCT00599040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The DASH diet with weight loss
Description: A reduced calorie diet is provided to participants based on the DASH diet.
Study NCT00599040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The DASH diet without weight loss
Description: participants are given a weight maintainenance diet based on the DASH diet
Study NCT00599040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dairy diet
Description: participants are given a high dairy, reduced calorie diet
Study NCT04453046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopurifier
Description: Two Hemopurifier treatments on Day 1 and Day 21
Study NCT04453046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200mg IV
Description: Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
Study NCT03998046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outreach Support for Weight Loss Goal Setting and Self-Weighing
Description: Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
Study NCT03998046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach Support for Weight Loss Goal Setting and Self-Weighing
Description: Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
Study NCT03998046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions
Description: Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks.
Study NCT03998046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions
Description: Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks.
Study NCT03998046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support
Description: Data received into the electronic health record from the cellular network-enabled electronic scale will categorize each patient based on their daily self-weighing behaviors and rate of progress towards their weight loss goal. Patients who are not engaged in daily self-weighing or are not making progress towards their goal will receive more intensive outreach support in the form of automated weekly MyChart problem solving messages, more frequent encouragement to access a broader array of community resources, and telephonic support from a nurse care coordinator who is an existing member of the primary care team. Support from this nurse care coordinator will be facilitated by the incorporation of each patient's self-weighing data into an EpicCare patient dashboard accessible to the nurse coordinator and other members of the care team
Study NCT04705194 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Resection of one or more liver segments as treatment for primary or metastatic liver cancer
Study NCT04705194 — intervention group
Intervention type: PROCEDURE
Intervention: PVE or ALPPS
Description: Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
Study NCT02431572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBR PET
Study NCT02431572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cancer Immunotherapy
Description: Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
Study NCT02431572 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation and chemotherapy
Description: Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
Study NCT02102321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole
Study NCT02102321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT01265550 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nissen fundoplication
Description: laparoscopic antireflux surgery
Study NCT01265550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: baclofen
Description: Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved.
Study NCT01265550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Desipramine
Description: Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
Study NCT01783704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUSH
Description: Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
Study NCT01783704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PULSE
Description: During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
Study NCT03685539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Computed Tomography
Description: Undergo DECT
Study NCT02121457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazil nut
Description: Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
Study NCT02121457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Study NCT04791774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein (food grade protein)
Description: Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein
Study NCT04791774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fee amino acids (food grade amino acids)
Description: Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine
Study NCT04450121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be intubated using Air-Q airway
Description: Both groups:~Grade 1: Split airway provides an unobstructed path for bronchoscope from mouth to glottis.~Grade 2: Tongue rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 3: Epiglottis rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 4: Tongue and epiglottis rest against posterior pharyngeal wall, both causing partial obstruction to bronchoscope.~Grade 5: Tongue rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure).~Grade 6: Epiglottis rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure)
Study NCT00864435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg Tablets, single dose
Description: A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
Study NCT00864435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coreg® 12.5 mg Tablets , single dose
Description: B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
Study NCT02592239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional brain MRI
Description: Functional brain MRI before and after test meal ingestion